Aurinia Pharmaceuticals Inc (NASDAQ: AUPH): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Stocks Info

AUPH belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Aurinia Pharmaceuticals Inc is $734.67M. A total of 1.16 million shares were traded on the day, compared to an average of 2.42M shares.

In the most recent transaction, Greenleaf Peter sold 126,981 shares of AUPH for 5.60 per share on Mar 06 ’24. After the transaction, the Chief Executive Officer now owns 1,522,114 company shares. In a previous transaction on Mar 06 ’24, Robertson Stephen P. sold 57,745 shares at 5.60 per share. AUPH shares that EVP, General Counsel owns now total 443,824.

Among the insiders who sold shares, Donley Matthew Maxwell disposed of 40,665 shares on Mar 06 ’24 at a per-share price of $5.51. This resulted in the EVP, Ops & Strategy holding 584,072 shares of AUPH after the transaction. In another insider transaction, Miller Joseph M sold 34,811 shares at $5.60 per share on Mar 06 ’24. Company shares held by the Chief Financial Officer now total 495,928.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, AUPH has a high of $12.43 and a low of $4.85.

As of this writing, AUPH has an earnings estimate of -$0.14 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $0.01 per share and a lower estimate of -$0.2. The company reported an EPS of -$0.09 in the last quarter, which was 47.10% higher than expectations of -$0.17.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. AUPH’s latest balance sheet shows that the firm has $466.08M in Cash & Short Term Investments as of fiscal 2021. There were $8.74M in debt and $40.65M in liabilities at the time. Its Book Value Per Share was $2.63, while its Total Shareholder’s Equity was $479.09M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AUPH is Buy with a score of 4.29.

Most Popular

Related Posts